Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Abstract Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites. Among nosocomial pneumonia subtypes, ventilated HABP (vHABP) is associated with the lowest survival....

Full description

Bibliographic Details
Main Authors: Jean-François Timsit, Jennifer A. Huntington, Richard G. Wunderink, Nobuaki Shime, Marin H. Kollef, Ülo Kivistik, Martin Nováček, Álvaro Réa-Neto, Ignacio Martin-Loeches, Brian Yu, Erin H. Jensen, Joan R. Butterton, Dominik J. Wolf, Elizabeth G. Rhee, Christopher J. Bruno
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Critical Care
Subjects:
Nosocomial pneumonia
HABP/VABP
Mechanical ventilation
Pseudomonas aeruginosa
ESBL
All-cause mortality
Online Access:https://doi.org/10.1186/s13054-021-03694-3

Internet

https://doi.org/10.1186/s13054-021-03694-3

Similar Items